The invention of intracoronary stents greatly increased the safety and applicability of
percutaneous coronary interventions. At this time,> 1 million coronary stent implantations are …

Background P2Y 12 receptor antagonist therapy is recommended in addition to ASA for up
to 1 year after acute coronary syndrome to reduce ischemic events. In contrast, the benefit of …

Background Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

Background: The optimal duration of dual antiplatelet therapy (DAPT) following second-
generation drug-eluting stent (DES) implantation is still debated. Objectives: The aim of this …

Background Optimum duration of dual antiplatelet treatment (DAPT) after coronary stenting
remains uncertain, with an unknown efficacy to safety ratio of extended treatment leading to …

Background—The risks and benefits of long-term dual antiplatelet therapy remain unclear.
Methods and Results—This prospective, multicenter, open-label, randomized comparison …

Aim The optimal duration of dual antiplatelet therapy (DAPT) following the use of new
generation drug-eluting stents is unknown. Methods and results The association between …

Background and Purpose—The efficacy and safety of different antiplatelet regimes for
prevention of stroke in patients at high risk were investigated in a systematic review and …

Coronary artery bypass grafting (CABG)-related bleeding complications and perioperative
coronary events are strongly influenced by the management of antithrombotic therapy before …